This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Oncology Podcasts

Episode 1

Xofigo

Why treat with Xofigo®▼ (radium-223 dichloride)?

Description

Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible metastatic castration-resistant prostate cancer (mCRPC) patients in their clinics.

Speakers:

  • Dr Omi Parikh - Consultant Clinical Oncologist, Lancashire Teaching Hospitals NHS Foundation Trust
  • Ellie Cradock - Molecular Radiotherapy Manager, University Hospitals Bristol and Weston NHS Foundation Trust

 

This promotional podcast series has been initiated and funded by Bayer and is for healthcare professionals only.

Speakers

PP-XOF-GB-0679 | September 2025